MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) is actively highlighting six studies published in 2022. The data across these studies demonstrate favorable outcomes with the use of OviTex Reinforced Tissue Matrix that support its use as a better alternative to traditional synthetic and biologic mesh products.
It is estimated that over two million hernia repairs will be performed this year within the United States, Europe, and the United Kingdom. Of critical importance to surgeons and patients is the incorporation of a hernia reinforcement material that will help limit the potential for complications such as infection and hernia recurrence.
Launched in June 2016, OviTex has been rigorously studied in the clinical setting since its commercialization. Recently, two European and four US-published clinical studies demonstrated favorable outcomes with the use of OviTex Reinforced Tissue Matrix.1–6 These publications evaluated a total of 280 OviTex patients in both prospective and retrospective studies across a range of patient characteristics, procedural approaches, and planes of placement, including bridged repair. Three studies directly compared OviTex to pure biologics or permanent synthetics, with favorable results for OviTex. These favorable outcomes included lower complication rates and lower recurrence rates for OviTex in comparison to pure biologics1,5, as well as lower surgical site occurrences and similar recurrence rates for OviTex in comparison to permanent synthetics6.
“We are pleased to showcase these six studies,” said Marissa Conrad, Vice President of Clinical Affairs. “As hernia patients become more educated about their treatment options, it’s important they are aware of published research demonstrating that effective, more natural materials are available for their repair.”
- Sivaraj, D.; Henn, D.; Fischer, K. S.; Kim, T. S.; Black, C. K.; Lin, J. Q.; Barrera, J. A.; Leeolou, M. C.; Makarewicz, N. S.; Chen, K.; Perrault, D. P.; Gurtner, G. C.; Lee, G. K.; Nazerali, R.* Reinforced Biologic Mesh Reduces Postoperative Complications Compared to Biologic Mesh after Ventral Hernia Repair. Plastic Reconstr Surg – Global Open 2022, 10 (2), e4083. DOI: 10.1097/GOX.0000000000004083
- G., 3rd DeNoto.* Bridged Repair of Large Ventral Hernia Defects Using an Ovine Reinforced Biologic: A Case Series. Ann Medicine Surg 2022, 75, 103446. DOI: 10.1016/j.amsu.2022.103446
- Timmer, A. S.; Claessen, J. J. M.; Koning, I. M. B. de; Haenen, S. M.; Belt, E. J. T.; Bastiaansen, A.; Verdaasdonk, E. G. G.; Wolffenbuttel, C. P.; Schreurs, W. H.; Draaisma, W. A.; Boermeester, M. A.* Clinical Outcomes of Open Abdominal Wall Reconstruction with the Use of a Polypropylene Reinforced Tissue Matrix: A Multicenter Retrospective Study. Hernia 2022, 26 (5), 1241–1250. DOI: 10.1007/s10029-022-02604-y
- DeNoto, G.; Ceppa, E. P.; Pacella, S. J.; Sawyer, M.; Slayden, G.; Takata, M.; Tuma, G.; Yunis, J.* 24-Month Results of the BRAVO Study: A Prospective, Multi-Center Study Evaluating the Clinical Outcomes of a Ventral Hernia Cohort Treated with OviTex® 1S Permanent Reinforced Tissue Matrix. Ann Medicine Surg 2022, 83, 104745. DOI: 10.1016/j.amsu.2022.104745
- Goetz, M.; Jurczyk, M.; Junger, H. J.; Brunner, S. M.; Brennfleck, F. W.* Semiresorbable biologic hybrid meshes for ventral abdominal hernia repair in potentially contaminated settings: lower risk of recurrence. Updates Surg. 2022 Dec;74(6):1995-2001. DOI: 10.1007/s13304-022-01378-3
- Sivaraj, D.; Fischer, K. S.; Kim, T. S.; Chen, K.; Tigchelaar, S. S.; Trotsyuk, A. A.; Gurtner, G. C.; Lee, G. K.; Henn, D.; Nazerali, R. S.* Outcomes of Biosynthetic and Synthetic Mesh in Ventral Hernia Repair. Plastic Reconstr Surg – Global Open 2022, 10 (12), e4707. DOI: 10.1097/GOX.0000000000004707
*Indicates one or more surgeons are paid consultants of TELA Bio, Inc.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.